| Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects JL Jiménez, V Stalbovskaya, B Jones Pharmaceutical statistics 18 (3), 287-303, 2019 | 23 | 2019 |
| Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents JL Jimenez, M Tighiouart, M Gasparini Biometrical Journal 61 (2), 319-332, 2019 | 19 | 2019 |
| A Bayesian seamless phase I–II trial design with two stages for cancer clinical trials with drug combinations JL Jiménez, S Kim, M Tighiouart Biometrical Journal 62 (5), 1300-1314, 2020 | 11 | 2020 |
| Quantifying treatment differences in confirmatory trials under non-proportional hazards JL Jiménez Journal of Applied Statistics 49 (2), 466-484, 2022 | 10 | 2022 |
| Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance D Magirr, JL Jiménez Clinical Trials 19 (2), 201-210, 2022 | 6 | 2022 |
| Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials JL Jiménez, M Tighiouart Journal of the Royal Statistical Society Series C: Applied Statistics 71 (5 …, 2022 | 4 | 2022 |
| A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching JL Jiménez, J Niewczas, A Bore, CF Burman Plos one 16 (11), e0259178, 2021 | 4 | 2021 |
| Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? M Tighiouart, JL Jiménez, MA Diniz, A Rogatko Brazilian journal of biometrics 40 (4), 453, 2022 | 2 | 2022 |
| Response to comments on" Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and … JL Jiménez, V Stalbovskaya, B Jones Pharmaceutical statistics 19 (5), 736-740, 2020 | 1 | 2020 |
| Visualizing hypothesis tests in survival analysis under anticipated delayed effects JL Jiménez, I Barrott, F Gasperoni, D Magirr Pharmaceutical Statistics, 2024 | | 2024 |
| A Bayesian adaptive design for dual‐agent phase I–II oncology trials integrating efficacy data across stages JL Jiménez, H Zheng Biometrical Journal 65 (7), 2200288, 2023 | | 2023 |
| Stratified modestly weighted log‐rank tests in settings with an anticipated delayed separation of survival curves D Magirr, JL Jiménez Biometrical Journal 65 (4), 2200126, 2023 | | 2023 |
| A Bayesian design for dual-agent dose optimization with targeted therapies JL Jiménez, M Tighiouart arXiv preprint arXiv:2210.08894, 2022 | | 2022 |
| Designs of Early Phase Cancer Trials with Drug Combinations JL Jiménez, MA Diniz, A Rogatko, M Tighiouart Modern Statistical Methods for Health Research, 131-160, 2021 | | 2021 |
| Innovative adaptive designs in oncology clinical trials with drug combinations JL Jiménez Politecnico di Torino, 2018 | | 2018 |
Mourad TighiouartProfessor, Cedars-Sinai Medical Center在 cshs.org 的电子邮件经过验证
